openPR Logo
Press release

United States Hodgkin's Lymphoma Market Size to Reach US$ 2.1 Billion by 2031 at 9.8% CAGR, Driven by Rising Cancer Prevalence and Advancements in Targeted Therapies | Merck & Co., Inc., Bristol Myers Squibb, F. Hoffmann-La Roche Ltd

09-24-2025 09:22 AM CET | Health & Medicine

Press release from: DataM Intelligence 4market Research LLP

Hodgkin's Lymphoma Market

Hodgkin's Lymphoma Market

The Global Hodgkin's Lymphoma Market reached US$ 0.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.1 billion by 2031. The global Hodgkin's lymphoma market is expected to exhibit a CAGR of 9.8% during the forecast period (2024-2031).

The Hodgkin's Lymphoma Market revolves around treatments, diagnostics, and drugs developed to manage this cancer affecting the lymphatic system. Increasing prevalence of lymphoma and improved survival rates through targeted therapies are fueling growth. Immunotherapies, monoclonal antibodies, and stem cell transplants are gaining prominence. Governments and health organizations are investing heavily in cancer research and patient care. The rising availability of advanced diagnostic tools is aiding early detection and personalized treatment approaches. Collaborations between pharma companies and research institutions are further boosting innovation in this market.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Hodgkin's Lymphoma Market Landscape:- https://datamintelligence.com/download-sample/hodgkin-lymphoma-market?rk

☛ Hodgkin's Lymphoma Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In March 2025, Foresight Diagnostics launched the PRECISE-HL clinical trial with major cancer centers to evaluate ctDNA-based MRD detection in advanced classical Hodgkin lymphoma. The study aims to enable therapy de-escalation in patients who respond early to treatment.

✅ In June 2025, ADCETRIS® (brentuximab vedotin) in combination with ECADD received regulatory approval in Europe, with potential impact on U.S. treatment strategies. The Phase 3 HD21 trial demonstrated improved outcomes for newly diagnosed Stage IIb-IV Hodgkin lymphoma patients.

Japan: Recent Industry Developments

✅ In recent years, Japan approved ADCETRIS® (brentuximab vedotin) in combination with AVD as a frontline therapy for CD30-positive Hodgkin lymphoma. The approval was based on results from the Phase 3 ECHELON-1 trial and broadened treatment access for newly diagnosed patients.

✅ In 2025, ongoing Japanese clinical trial activity continued around novel agents for hematologic cancers, with several investigational drugs in lymphoma that may provide translational insights for Hodgkin's lymphoma therapies. These trials aim to strengthen Japan's oncology pipeline.

☛ Hodgkin's Lymphoma Market Trends:

The Hodgkin's lymphoma market is driven by advancements in targeted therapies, immunotherapies, and combination treatments that enhance patient survival rates. Rising cancer incidence, along with increasing healthcare awareness and early screening programs, are fueling demand for effective treatment options.

Strong investments in R&D by pharmaceutical companies and clinical trials for novel drugs are shaping the market landscape. Additionally, the adoption of precision medicine and biomarker-based therapies is expanding personalized treatment approaches, improving outcomes, and driving market innovation.

☛ Hodgkin's Lymphoma Market Competitve Landscape:

Merck & Co., Inc., Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Seagen Inc., Ono Pharmaceutical Co., Ltd., AstraZeneca, Inc., Actinium Pharmaceuticals, Inc., Pfizer Inc., Affimed GmbH and Incyte.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/hodgkin-lymphoma-market

☛ Segment Covered in the Hodgkin's Lymphoma Market:

By Therapy: Targeted Therapy | Chemotherapy | Immunotherapy | Others

By Type: Nodular Sclerosis Hodgkin Lymphoma | Mixed Cellularity Hodgkin Lymphoma | Lymphocyte-Rich Hodgkin Lymphoma | Lymphocyte-Depleted Hodgkin Lymphoma

By Distribution Channel: Hospitals | Clinics | Cancer Centers | Others

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Hodgkin's Lymphoma Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=hodgkin-lymphoma-market

☛ Regional Analysis for Hodgkin's Lymphoma Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

☛ Frequently asked questions:

➠ What is the global sales, production, consumption, import, and export value of the Hodgkin's Lymphoma Market?
➠ Who are the key global manufacturers, and what is their operational performance?
➠ What are the major opportunities and threats in the global Hodgkin's Lymphoma Market?
➠ Which product types or end-users show the most growth potential and market share?
➠ What challenges and constraints are impacting the Hodgkin's Lymphoma Market?
➠ What sales, marketing, and distribution channels are used globally?

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release United States Hodgkin's Lymphoma Market Size to Reach US$ 2.1 Billion by 2031 at 9.8% CAGR, Driven by Rising Cancer Prevalence and Advancements in Targeted Therapies | Merck & Co., Inc., Bristol Myers Squibb, F. Hoffmann-La Roche Ltd here

News-ID: 4195269 • Views:

More Releases from DataM Intelligence 4market Research LLP

Japan CAR-T Cell Therapy Market Forecast 2025-2033: Advancements in Allogeneic Therapies and Combination Treatments | Key Japanese Pharmaceutical Players Invest in Next-Gen CAR-T Cell Technologies
Japan CAR-T Cell Therapy Market Forecast 2025-2033: Advancements in Allogeneic T …
The Japan CAR-T cell therapies market reached US$ 346.00 million in 2024 and is expected to reach US$ 1,350.15 million by 2033, growing at a CAGR of 16.3% during the forecast period 2025-2033. The CAR-T Cell Therapies Market in Japan involves genetically engineered T-cells targeting cancer-specific antigens. Growth is driven by rising cancer incidence, advanced immunotherapies, and government support. Hospitals and specialized oncology centers are key end-users. Clinical trials focus on
Advanced Rocket and Missile Propulsion Systems Market to Reach USD 77.58 Billion by 2032 | Driving Innovations in Hypersonics and Green Propellants
Advanced Rocket and Missile Propulsion Systems Market to Reach USD 77.58 Billion …
Global Advanced Rocket and Missile Propulsion Systems Market size reached US$ 38.79 billion in 2024 and is expected to reach US$ 77.58 billion by 2032, growing with a CAGR of 9.05% during the forecast period 2025-2032. Advanced Rocket and Missile Propulsion Systems include solid, liquid, and hybrid engines used in defense, space, and aerospace applications. Growth is driven by defense modernization, space exploration, and missile defense initiatives. Technologies focus on high
Transparent Food Labeling Market to Reach USD 79.21 Billion by 2032, Growing at a CAGR of 7.87% | Increasing Demand for Organic, Non-GMO, and Allergen-Free Labels
Transparent Food Labeling Market to Reach USD 79.21 Billion by 2032, Growing at …
Global transparent food labeling market size reached US$ 43.21 billion in 2024 and is expected to reach US$ 79.21 billion by 2032, growing with a CAGR of 7.87% during the forecast period 2025-2032. Transparent Food Labeling involves providing clear, accurate information about ingredients, nutritional content, and allergens on packaged foods. Growth is driven by rising consumer awareness, health consciousness, and regulatory requirements. Labels often highlight organic, non-GMO, or allergen-free claims.
Regulatory Technology Market Outlook 2025-2032: Expansion in Cloud-Based and AI-Powered Compliance Tools | AI-Driven Analytics and Blockchain Enhance Efficiency in RegTech Compliance and Reporting
Regulatory Technology Market Outlook 2025-2032: Expansion in Cloud-Based and AI- …
Global RegTech Market reached US$ 20.04 billion in 2024 and is expected to reach US$ 33.36 billion by 2032, growing with a CAGR of 6.75% during the forecast period 2025-2032. The Regulatory Technology (RegTech) Market provides software and tools to ensure compliance, risk management, and reporting for financial institutions. Growth is driven by increasing regulations, fintech adoption, and fraud prevention needs. Solutions include AI-driven analytics, blockchain, and automated reporting systems.

All 5 Releases


More Releases for Hodgkin

Hodgkin Lymphoma Treatment Market Poised to Reach USD 15.70 Bn by 2030 at 8.3% C …
Opening Paragraph According to a new report by Maximize Market Research, the global Hodgkin Lymphoma Treatment Market was valued at USD 8.98 billion in 2023 and is projected to reach nearly USD 15.70 billion by 2030, growing at a CAGR of 8.3%. Curious to peek inside? Grab your sample copy of this report now:https://www.maximizemarketresearch.com/request-sample/124690/ Key Highlights Market Size & CAGR: Valued at USD 8.98 Bn in 2023, forecast to grow to USD 15.70
High Prevalence Of Non-Hodgkin Lymphoma Fuels Market Growth: The Driving Engine …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Non Hodgkin Lymphoma (NHL) Market Size Growth Forecast: What to Expect by 2025? The market size for non hodgkin lymphoma (NHL) has consistently seen robust growth in recent times. It is anticipated to expand from $10.11 billion in 2024 to $11.01 billion in 2025, with a compound annual growth
Breakthrough Treatments for Non-Hodgkin Lymphoma
The Business Research Company recently released a comprehensive report on the Global Non Hodgkin Lymphoma (NHL) Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The non hodgkin
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight
The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017 | Market R …
Market Research Hub (MRH) has recently published a latest market study to its online portal, which is titled as “Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017” This study offers professional analysis of the current state of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market. Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1049067 Market Research HUB’s latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Review, H1 2017, provides
Non-Hodgkin Lymphoma - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Non-Hodgkin Lymphoma - Heat Map and Analysis to its growing collection of premium market research reports. Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing)